High-Dose Glucocorticoids for Hypophysitis Are Worse in Melanoma Patients
Melanoma patients who were treated with glucocorticoids for ipilimumab-induced hypophysitis had improved survival outcomes if they received low doses. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

BMS ’ Opdivo/Yervoy combo cleared for kidney cancer
Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.07/16/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 16, 2018 Category: Urology & Nephrology Source Type: news

Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.-- July 11, 2018 (BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval from the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 11, 2018 Category: Drugs & Pharmacology Source Type: news

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma
In the CheckMate 214 trial, Motzer et al found higher overall survival among intermediate- and poor-risk patients with previously untreated metastatic renal-cell carcinoma who received nivolumab plus ipilimumab than among those who received sunitinib07/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 10, 2018 Category: Urology & Nephrology Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Oncolytic Virus Plus Ipilimumab Improves Responses in Advanced Melanoma
The combination of an oncolytic virus with ipilimumab yielded a significantly higher response rate vs ipilimumab alone in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safe...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers find combination can enhance ipilimumab immunotherapy
(University of Texas M. D. Anderson Cancer Center) Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 15, 2018 Category: Cancer & Oncology Source Type: news

Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up
Dave LevitanJun 6, 2018After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Dave LevitanJun 5, 2018Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
(Tonic Life Communications USA) Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy ® ). Current data show an overall response rate of 38 percent following treatment with the combination of tilsotolimod and ipilimumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2018 Category: International Medicine & Public Health Source Type: news

No Reliable Predictors for Ipilimumab-Induced Hypophysitis No Reliable Predictors for Ipilimumab-Induced Hypophysitis
Study results highlight the need for endocrine monitoring of all patients receiving checkpoint inhibitor immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 29, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Risk Factors for Ipilimumab-Induced Hypophysitis Remain Unclear
(MedPage Today) -- Researchers recommend close monitoring of these patients (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 18, 2018 Category: Dermatology Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 2, 2018 Category: Health Management Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 2, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 1, 2018 Category: American Health Authors: Ron Leuty Source Type: news

How Bristol-Myers Squibb's new Peninsula digs boost its battle to beat cancer
Cancer's zigs and zags to avoid detection and destruction may come to a dead end in a 62,000-square-foot Redwood City building. Bristol-Myers Squibb Co. opened the third of its three-structure West Coast research center, where the New York-based drug giant has zeroed in on antibodies that stoke the immune system's battle against cancer. But while so-called cancer immunotherapies, such as BMS's Yervoy and Opdivo, produced s tunning results in some patients, most don't respond and some relapse. That's… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 1, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Preferred First-line Treatment for Metastatic Kidney Cancer Preferred First-line Treatment for Metastatic Kidney Cancer
Indirect comparisons suggest that of available agents, cabozantinib or nivolumab plus ipilimumab may be the most effective first-line treatment for metastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab/Ipilimumab Combo Approved for Advanced RCC
In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2018 Category: Cancer & Oncology Authors: Dylan Fisher Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

FDA approves Opdivo, Yervoy combination for kidney cancer
The Food and Drug Administration has approved a combination of two immunotherapy drugs, ipilimumab and nivolumab, to treat metastatic kidney cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 17, 2018 Category: Consumer Health News Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

FDA approves new standard of care for kidney cancer
(UT Southwestern Medical Center) The US Food and Drug Administration granted approval to the combination of two immunotherapy drugs, ipilimumab and nivolumab, for the treatment of metastatic kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2018 Category: International Medicine & Public Health Source Type: news

FDA Approves IO Combo for Advanced Renal Cell Cancer FDA Approves IO Combo for Advanced Renal Cell Cancer
The approval of the nivolumab and ipilimumab combination provides a new first-line treatment option for a segment of patients with advanced renal cell carcinoma.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Adjuvant Pembrolizumab Beneficial in Metastatic NSCLC
MONDAY, April 16, 2018 -- For metastatic non-small-cell lung cancer (NSCLC), the addition of pembrolizumab to standard chemotherapy is beneficial; and nivolumab plus ipilimumab is associated with better survival than chemotherapy for NSCLC with high... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2018 Category: Pharmaceuticals Source Type: news

Drug Combo Wins OK as First Line in Kidney Cancer
(MedPage Today) -- As shown in Checkmate 214 study, ipilimumab + nivolumab improve survival (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 16, 2018 Category: Urology & Nephrology Source Type: news

New Studies Show Immune Treatments Could Be Key in the Fight Against Lung Cancer
Researchers report some of the most encouraging results yet for treating lung cancer with the latest immune-based treatments, most of which have been approved to treat other types of tumors. In three papers presented at the American Association for Cancer Research annual meeting, and published simultaneously in the New England Journal of Medicine, lung cancer experts found innovative ways to weaken lung tumors to improve people’s chances of surviving the disease. “There is definitely a high unmet need,” says Patrick Forde, assistant professor of oncology and associate member of the Bloomberg-Kimmel Instit...
Source: TIME: Health - April 16, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer cancer immunotherapy Source Type: news

Adding Merck's Keytruda To Chemo Halves Death Risk For Lung Cancer Patients
Another study combined Opdivo and Yervoy, two drugs made by Bristol-Myers Squibb, in lung cancer patients selected with a new type of diagnostic test. An third result hints that giving Opdivo earlier – before surgery to remove tumors – may lead to even more benefits for patients. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 16, 2018 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:MRK NYSE:BMY Source Type: news

Adjuvant Pembrolizumab for Melanoma -- Approval Imminent? Adjuvant Pembrolizumab for Melanoma -- Approval Imminent?
Pembrolizumab is poised to join the ranks of ipilimumab and nivolumab as adjuvant therapy for patients with stage III melanoma, after showing a 43% reduction in risk for recurrence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) Combination as First-Line Treatment for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) April 16, 2018 --Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2018 Category: Drugs & Pharmacology Source Type: news

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer
WEDNESDAY, April 11, 2018 -- Gemcitabine and cisplatin (GC) plus ipilimumab is associated with a 69 percent objective response rate and 61 percent one-year overall survival for patients with metastatic urothelial cancer, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2018 Category: Pharmaceuticals Source Type: news

Outcomes in Melanoma After Stopping Nivolumab and Ipilimumab Outcomes in Melanoma After Stopping Nivolumab and Ipilimumab
Many patients continue to derive benefit from combined nivolumab and ipilimumab after discontinuation.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 11, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Nivolumab/Ipilimumab Combo Bests Sunitinib in Advanced RCC
A phase III study by Dr. Robert Motzer and colleagues in NEJM found significantly higher OS and ORRs with the immunotherapy combination. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology News Renal Cell Carcinoma Source Type: news

Nivolumab, ipilimumab combination improves advanced renal cell carcinoma survival
Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.04/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 4, 2018 Category: Urology & Nephrology Source Type: news

Immunotherapy Drugs Causing Vision Issues
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss. The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma. All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers. The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - March 27, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Nivolumab Plus Ipilimumab Tops Sunitinib for Advanced Renal CA
Overall survival, objective response higher than sunitinib for untreated clear - cell advanced RCC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 23, 2018 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news

Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Bristol-Myers Squibb and Nektar Therapeutics announce global development & commercialization collaboration for Nektar's CD122-biased agonist, NKTR-214
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced the companies have executed a global strategic development and commercialization collaboration for Nektar's lead immuno-oncology program, NKTR-214. Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in (Source: World Pharma News)
Source: World Pharma News - February 15, 2018 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Only U.S. Cryotherapy Trial for Mesothelioma Finds Success
Thoracic surgeon Dr. Shanda Blackmon at the Mayo Clinic in Rochester, Minnesota, believes there is a place for cryotherapy in the future multidisciplinary treatment of pleural mesothelioma. She wants to show it with this groundbreaking clinical trial. “We think [cryotherapy] could play an important role in treatment,” Blackmon told Asbestos.com. “So far, things look promising, but you can’t say anything specific without more numbers. Right now, it’s a little like telling a story.” Cryotherapy involves destroying cancer cells, or any abnormal tissues, by freezing them with controlled nitr...
Source: Asbestos and Mesothelioma News - February 14, 2018 Category: Environmental Health Authors: Daniel King Tags: ADI-PEG 20 cryoablation cryotherapy intrapleural measles virus Mayo Clinic mesothelioma clinical trial Opdivo pacific mesothelioma center pleural mesothelioma pleuroscopy Shanda Blackmon Surgery for Mesothelioma After Radiation Thera Source Type: news

Nivolumab's Durable Responses in MMR/MSI Colorectal Cancer Nivolumab's Durable Responses in MMR/MSI Colorectal Cancer
Nivolumab as monotherapy or in combination with ipilimumab produced durable clinical responses in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab Plus Ipilimumab Offers Improved Survival Outcomes in Certain Metastatic CRC Patients
Patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer who received nivolumab along with ipilimumab had high response rates and improved survival outcomes compared with those who received nivolumab alone. (Source: CancerNetwork)
Source: CancerNetwork - January 23, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer News Source Type: news

Immunotherapy Combo Active in High-Risk CRC
(MedPage Today) -- Disease control in 80% with nivolumab-ipilimumab (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 22, 2018 Category: Gastroenterology Source Type: news

Top 10 Mesothelioma News Stories of 2017
Every year, mesothelioma specialists and researchers make strides to advance the standard of care, improve treatment strategies and develop new diagnostic practices. Mesothelioma remains a rare cancer, with an estimated 3,000 people diagnosed each year in the U.S., but the fight to find a cure only grows stronger. And while researchers are busy finding breakthroughs in care, advocates are hard at work campaigning for a ban on asbestos, the main cause of mesothelioma. This was a memorable year on both fronts. Immunotherapy continues to be the hot topic among emerging treatments. Drugs such as pembrolizumab (Keytruda) and ni...
Source: Asbestos and Mesothelioma News - December 22, 2017 Category: Environmental Health Authors: Daniel King Tags: canada asbestos ban Food and Drug Administration Furthering Asbestos Claims Transparency Act keytruda Medical marijuana mesothelioma mesothelioma vaccine Opdivo Scott Pruitt talcum powder lawsuit yervoy Source Type: news

Peninsula drug maker's Son of Yervoy dares cancer to pull off its mask
Bristol-Myers Squibb's Yervoy was a cutting-edge cancer immunotheapy. Now it's teamed with a South San Francisco company to take a new version of the drug, potentially with fewer side effects, into clinical trials. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 29, 2017 Category: American Health Authors: Ron Leuty Source Type: news

Peninsula drug maker's Son of Yervoy dares cancer to pull off its mask
Bristol-Myers Squibb's Yervoy was a cutting-edge cancer immunotheapy. Now it's teamed with a South San Francisco company to take a new version of the drug, potentially with fewer side effects, into clinical trials. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 29, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Oncolytic Virus Succeeds in Melanoma Trial (CME/CE)
(MedPage Today) -- Add-on to ipilimumab better than drug alone (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 10, 2017 Category: Dermatology Source Type: news

Adjuvant Ipilimumab in Melanoma: Future in Doubt Adjuvant Ipilimumab in Melanoma: Future in Doubt
This hugely expensive regimen has now been eclipsed by the checkpoint inhibitor nivolumab, placing the future of adjuvant ipilimumab under question, argues one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Merck Hedges Bets With Keytruda Lung Study
Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with Yervoy, a drug made by rival Bristol-Myers Squibb. But don't interpret the study as a bet the combination will prove effective. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 6, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news

First Randomized Study To Evaluate IMLYGIC ® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
Results Demonstrated a Doubling of Objective Response Rate Compared to Ipilimumab Alone in Unresectable Advanced Melanoma Responses Were Not Limited to Injected Lesions and Favored the Combination Arm Across Subsets of Disease THOUSAND OAKS, Calif., Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary endpoint of objective response rate (ORR), demonstrating that IMLYGIC in combination with YERVOY® (ipilimumab) more than doubled ORR, define...
Source: Amgen News Release - October 5, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Three-year survival rates with advanced melanoma are 52% with nivolumab and 34% with ipilimumab, but 58% with a sequential combination of the two, according to the latest results comparing the two anticancer biologics separately and together.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news